Skip to main content

Strategic Investment Facilitates Market Entry in China and Advances Ophthalmic Technology Evolving Ultrasound for Corneal Refractive and Cataract Surgery

CHICAGO — Auctus Capital Partners is pleased to announce its role as advisor to ArcScan, Inc., supporting the commercial-stage ophthalmology equipment and ultrasound visualization technology company in securing a strategic equity investment from Shanghai Haohai Biological Technology Ltd [publicly traded on the Hong Kong (6826.HK) and Shanghai (688366.SS) stock exchanges] with a $11.15 million USD preferred series B investment. The transaction — which enables the client to accelerate growth strategies and facilitates entry into the $3 billion ophthalmology market in China — was led by Auctus and its Managing Director of Healthcare & Life Sciences John Duguid.

ArcScan provides state-of-the-art ophthalmic ultrasound visualization technology that depicts the true anatomy of the entire anterior segment of the eye, from the cornea to the posterior of the lens with patient seat times of just a few minutes. Its innovations have led to many issued and pending ArcScan patents.

The ArcScan Insight® 100 device and software produce high-resolution images of areas of the eye which are otherwise inaccessible with other existing instrumentation. The technology enables precision analysis with repeatable and reproducible data, resulting in improved diagnostic, surgical outcomes and management of eye disorders, diseases, and procedures, such as refractive errors, cataracts, and glaucoma.

“This investment is an important step for the future of ArcScan, which is well-positioned to become a global category leader,” said Duguid “Today, more than 70 million ophthalmology procedures are performed annually, representing a $17 billion global market with growth in China expected to rapidly increase to $4.7 billion by 2024 — and due to the success of accommodating intraocular lenses and the ever-growing refractive surgery market, intelligent imaging and precise measurements are more necessary than ever before.”

“We were extremely impressed with the team at Auctus Capital Partners, who understood our needs and managed the transaction diligently,” said Andrew Levien, President and CEO of ArcScan. “Identifying China as a major entry point with a large and fast-growing market, Auctus leveraged its experience and relationships in the region to identify strategic partners and drive the capital markets process forward.”

Working quickly to support ArcScan, Auctus Capital Partners performed due diligence, crafted marketing material in preparation for entry into capital markets, targeting strategic investors with expertise and key opinion leaders in the ophthalmology and eye care space. Auctus helped identify strategic relationships and advised during the negotiation process of the transaction with Haohai Biotechnologies Development Co, Ltd, which is the ophthalmology integration and development platform arm of Shanghai Haohai Biological Technology Co. Ltd, a major publicly traded medical specialty company.

“By aligning, ArcScan can better scale commercial distribution, drive clinical application development, and build strategic partnerships to further fuel growth globally, while Haohai acquires a unique capability to offer the gold standard in ophthalmology diagnostics with better imaging at lower costs, while diversifying its position in the ophthalmic industry in China,” Duguid added.

More information is available at

About Auctus Capital Partners

Auctus Capital Partners is a leading financial services and investment banking firm focused exclusively on creating value for the lower middle market. We specialize in merger & acquisition advisory, institutional private placements of debt and equity, financial restructuring, valuation, and strategic consulting. Our senior bankers have deep domain expertise across a range of industries, with the necessary foresight to navigate highly-complex transactions to maximize value and achieve optimal outcomes for clients.

About ArcScan, Inc.

ArcScan is a leading developer of breakthrough ophthalmic visualization technology that aims to globally advance and evolve medical imaging. The ArcScan Insight® 100 Device provides a complete visualization of the true anatomy of the entire anterior segment. It uses intelligent, high-frequency ultrasound technology to produce high-resolution images and enable precision analysis with repeatable and reproducible data. Clinical benefits include precision imaging behind the iris for better ICL/IOL sizing, comprehensive anterior segment measurement tracking for early glaucoma management and MIGS evaluation, and wide-angle cornea layer mapping for keratoconus screening and inlay evaluations.

Haohai Biotechnologies Development Co, Ltd

Haohai Biotechnologies Development Co, Ltd is the ophthalmology integration and development platform arm of Shanghai Haohai Biological Technology ((906826.HK) and (688366.SS)), a publicly-traded, medical specialty company. It provides R&D, manufacturing, and sales of biomedical products in China. with a focus on ophthalmology, medical aesthetics and wound healing, orthopedics, and anti-adhesion and hemostasis. It currently manufactures intraocular lens (IOL), medical sodium hyaluronate, medical chitosan, medical collage sponge, rhEGF, etc.

# # #



ArcScan, Inc.  | Jul 21, 2021

ArcScan, Inc. Signs Definitive Agreement for $11.15 Million Preferred Series B Investment with Shanghai Haohai Biological Technology Ltd.

GOLDEN, Colo., July 21, 2021 — ArcScan, Inc., the developer of state-of-the-art ophthalmic ultrasound imaging device “ArcScan Insight® 100, ” headquartered in Golden, Colorado, announces the execution of a Stock Purchase Agreement with Shanghai Haohai Biological Technology Ltd. (“Haohai”) that will result in a $11.15 million Preferred Series B investment into ArcScan, Inc. Haohai is a leading Chinese ophthalmology and medical aesthetics company headquartered in Shanghai, and is publicly traded on the Hong Kong (6826.HK) and Shanghai (688366.SH) stock exchanges.

YAFO Capital (Shanghai) and Auctus Capital Partners (Chicago) acted as financial advisors on this transaction for ArcScan, Inc.

“This transaction fits well with our long-term global strategy in ophthalmic markets. The breakthrough technology from ArcScan, Inc. not only meets the unmet medical needs in the ophthalmic imaging field, but also leverages with our global product portfolio to significantly improve post-surgical results in premium IOLs and PIOL implantations.” said Olivia Chen, Executive Director of Haohai Biological Technology Co. Ltd.

“We are thrilled to be a close partner with Haohai to help them further develop their rapidly expanding offering of implantable lenses and, at the same time, provide ArcScan a base from which to expand into the largest ophthalmology market in the world. This couldn’t be a better strategic fit.” said Andrew Levien, CEO and President of ArcScan, Inc.

ArcScan’s Technology

The ArcScan Insight® 100 imaging technology provides unmatched accuracy to obtain measurements in the entire anterior chamber of the eye. The device and software create a powerful platform that enables users to easily obtain stunning high-resolution images of the entire anterior segment in micron precision, including areas that cannot be imaged with current optical technologies. The Swept Beam Liquid Interface™ technology delivers dramatic developments in ultrasound imaging, unrivaled in its precision.

The ArcScan Insight® 100 uses core proprietary technology that was originally developed and patented at Columbia/Weill University. A mechanically controlled 50 MHz transducer scans the eye in an arc shaped motion with a curvature that approximates the anterior ocular surface.

ArcScan’s Insight® 100

The ArcScan Insight® 100 device is a precision, very-high-frequency ultrasound (“VHF-US”) device for imaging and measuring anterior chamber depth, angle-to-angle width, individual corneal layers, sulcus-to-sulcus width, and more—all with micron-level precision.

While the patient is comfortably seated and resting on an EyeSeal Disposable, the device scans the eye, non-invasively. ArcScan’s EyeSeal Disposables are used to enable the precision imaging while preventing cross-contamination between patients. Designed for functional efficiency and ease of use, the ArcScan Insight® 100 system is comprised of four main components: the ArcScan Insight® 100 Device, the Insight software package, the fluidics module, and the electronics unit.

The ArcScan Insight® 100 provides accurate biometry for pre–operative and post-operative IOL, premium IOL, and ICL. This allows the clinic to evaluate accurate lens position, tilt, and volume.

“The goal is to reduce lens exchanges and make them very rare, as opposed to the current 2% exchange rate,” says Dr. Dan Reinstein, Founder and Laser Eye Surgeon of London Vision Clinic and Chief Medical Officer of ArcScan. “The most advanced method for ICL sizing is to use the Insight 100 very-high-frequency digital ultrasound scanner to directly measure the area inside the eye, behind the iris where the lens will sit.”

About ArcScan, Inc.

ArcScan develops smart imaging technology and continually evolving ultrasound to provide ophthalmologists with new insights into the true anatomy of the anterior segment of the eye, including areas behind the iris. ArcScan’s mission is to enable better medicine in ophthalmology by driving improved outcomes in refractive, corneal, cataract, and glaucoma surgeries. To learn more about the company, please visit, and connect on TwitterLinkedInFacebookInstagram, and YouTube.

About Shanghai Haohai Biological Technology Co., Ltd.

Haohai Biological Technology Co., Ltd. is a leading company in the PRC focusing on the research and development and manufacturing and sales of biomedical materials. Haohai strategically targets fast-growing therapeutic areas including ophthalmology, medical aesthetics and wound care, orthopedics and anti-adhesion, and hemostasis.

SOURCE ArcScan, Inc.